A recent preprint suggests ibogaine triggers a short burst of metabolic stress in neurons. That stress is followed by a rebound in energy production and shifts in pathways tied to synaptic plasticity and repair.
The paper appeared on bioRxiv on October 2, 2026 (Oulton et al., doi: 10.64898/2026.09.29.755437). It has not been peer-reviewed. Everything in it comes from cell cultures and mouse tissue. There are no human clinical results.
Conflict of interest: Two co-authors, Abhi Pushparaj and Jonathan E. Dickinson, work with Ambio Life Sciences. Ambio is an ibogaine treatment provider we list in our directory. You can see their Mexico center profile here. The work was done together with researchers at Dalhousie University.
What they actually did
Researchers measured mitochondrial respiration and glycolysis in primary mouse cortical neurons using a Seahorse analyzer. They tested ibogaine at 3, 10, and 30 µM. They also tracked mitochondrial membrane potential and mitochondrial ROS.
In a separate experiment they gave female mice a single oral dose of 100 mg/kg ibogaine. That dose was scaled from typical human flood doses. They then ran proteomics on spinal cord samples and looked at nearly 10,000 proteins at several time points.
Main observations
Ibogaine quickly lowered mitochondrial function and glycolysis in the neuron cultures. The drop happened within minutes and got stronger at higher concentrations. Membrane potential rose first. Mitochondrial ROS increased afterward.
When they washed the drug out after four hours, energy production rebounded by the 24-hour mark. BDNF mRNA levels also went up. The authors read this as a form of metabolic preconditioning.
In the mouse spinal cord the drug produced a clear stress signature early on. AMPK signaling rose at the 15-minute mark. Oxidative phosphorylation, mTOR, and lipid synthesis pathways were suppressed between 15 minutes and 24 hours. Most of that stress signature had resolved by 72 hours.
At the same 72-hour point several pathways linked to synaptic plasticity, neurite growth, and repair were higher than in vehicle-treated animals.
The authors propose that the brief metabolic stress may reopen a window of heightened plasticity similar to early development. They point to possible involvement of the mitochondrial potassium channel mitoKv1.3 and the sigma-2 receptor, both of which ibogaine binds.
Connection to earlier neuroplasticity work
This mechanism sits next to older findings that ibogaine can raise GDNF and BDNF and restore certain forms of juvenile-like plasticity in animal models. We covered that broader picture in an earlier post: GDNF and Ibogaine: The 'Brain Fertilizer' Theory. The new preprint focuses more on an upstream metabolic trigger that could help drive some of those later changes.
Limits worth keeping in mind
This is still a preprint. Peer review has not happened yet.
All the data are preclinical. Moving from cultured neurons and mouse spinal cord to reliable effects in people is a large step that has not been tested here.
The study does not examine cardiac safety. QT prolongation and arrhythmia risk remain the most important documented concerns with ibogaine treatment.
The mouse dose was allometrically scaled from human flood doses. Direct comparisons of exposure between species need care.
Bottom line
The results give a plausible hypothesis for one way ibogaine might influence plasticity and repair. They do not show that the drug works safely or effectively in humans. Like most early ibogaine research, these findings need independent replication and peer review before stronger claims are justified.